How has been the historical performance of Concord Biotech?

Answer:The historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years.

Breakdown:
Concord Biotech's net sales have increased significantly from INR 712.93 crore in March 2022 to INR 1,200.09 crore in March 2025, reflecting a strong upward trend. Total operating income followed suit, rising from INR 712.93 crore to INR 1,200.09 crore in the same period. The company's total expenditure, excluding depreciation, also grew from INR 439.66 crore to INR 693.76 crore, indicating increased operational costs. Operating profit (PBDIT) rose from INR 296.69 crore in March 2022 to INR 550.78 crore in March 2025, demonstrating improved profitability. The profit before tax increased from INR 241.16 crore to INR 495.87 crore, while profit after tax surged from INR 178.57 crore to INR 372.96 crore, showcasing robust growth in net earnings. The earnings per share (EPS) also improved significantly from INR 16.72 to INR 35.53. On the balance sheet, total assets grew from INR 1,312.79 crore in March 2022 to INR 2,034.25 crore in March 2025, with total liabilities increasing from INR 1,312.79 crore to INR 2,034.25 crore. Cash flow from operating activities showed a slight decline from INR 265 crore in March 2024 to INR 244 crore in March 2025, while the net cash outflow was recorded at INR 14 crore in March 2025. Overall, Concord Biotech has demonstrated strong growth in sales, profits, and assets, indicating a positive financial trajectory.